Dr. Garcia Advances Aqualung Therapeutics to Human Clinical Trials
Jan. 28, 2022
Image
![2022 image of Dr. Joe "Skip" Garcia](/sites/default/files/styles/az_large/public/2022-09/news_2022_skip_garcia.jpeg?itok=UVqx68xH)
SWEHSC member, University of Arizona pulmonologist, and CEO and founder of Aqualung Therapeutics, Joe G.N. "Skip" Garcia, MD, recently closed on a major investment that will help advance his new lung inflammation treatment to human clinical trials. The drug, a monoclonal antibody known as ALT-100, will work to reduce lung inflammation and poor health outcomes from various respiratory diseases. Click here to read the full Arizona Daily Star article about Dr. Garcia.